Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modigraf (tacrolimus granules) pharmacokinetics and long-term safety in de novo pediatric liver and kidney transplant recipients
2022-002350-68Phase 4
- Sponsor
- Astellas Pharma
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mycophenolate mofetil in kidney transplant and graft rejection (2 arms), sponsored by Astellas Pharma. Primary endpoints: Pharmacokinetic parameters of tacrolimus on day 1 and day 7 (+7 days), Long-term safety of Modigraf and 1 more.
02
Drugs
mycophenolate mofetil
03
Conditions
kidney transplantgraft rejection
Beyond the preview
Go deeper on 2022-002350-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002350-68.